Literature DB >> 11907772

Transcatheter thrombolysis with high-dose bolus tissue plasminogen activator in iatrogenic arterial occlusion after femoral arterial catheterization.

Dimitrios K Tsetis1, George E Kochiadakis, Adam A Hatzidakis, Emannuel I Skalidis, Evangelia G Chryssou, Ioanna N Tritou, Panos E Vardas, Nicholas C Gourtsoyiannis.   

Abstract

PURPOSE: To assess the efficacy of percutaneous local thrombolysis with high-dose bolus recombinant tissue plasminogen activator (rt-PA) in patients with acute limb ischemia due to arterial thrombosis after cardiac catheterization.
METHODS: We treated eight patients (7 men; mean age 56 years) with thrombotic occlusion of both the common femoral artery (CFA) and external iliac artery (EIA) in six patients and of the CFA only in two patients. Two 5 mg boluses of rt-PA were injected into the proximal clot through a 5 Fr end-hole catheter and subsequently two additional boluses of 5 mg rt-PA were given through a catheter with multiple side-holes. In case of a significant amount of residual thrombus, a continuous infusion of 2.5 mg/hr of rt-PA was started.
RESULTS: Successful lysis was achieved in all patients. The mean duration of lysis was 2 hr 41 min. The mean total amount of rt-PA delivered was 23.16 mg. In four patients unmasked flow-limited dissections confined to the CFA were managed by prolonged balloon dilatation, while in the remaining four patients with extension of the dissection to the external iliac artery one or two Easy Wallstents were implanted. There was prompt relief of lower limb ischemic symptoms and signs in all patients. Two groin hematomas were conservatively treated. Clinical and color Doppler flow imaging follow-up with a mean duration of 15 months, showed no reappearance of ischemic symptoms or development of restenosis in any of the patients. One patient died 6 months after thrombolysis.
CONCLUSIONS: Transcatheter thrombolysis with high-dose bolus rt-PA is a safe and effective treatment in patients with iatrogenic arterial occlusion after femoral catheterization. Underlying dissections should be treated by prolonged balloon dilatation but stent implantation is often required.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907772     DOI: 10.1007/s00270-001-0061-3

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  6 in total

1.  Effects of Intravenous and Catheter Directed Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator (Alteplase) in Non-Traumatic Acute Limb Ischemia; A Randomized Double-Blind Clinical Trial.

Authors:  Abbas Saroukhani; Hassan Ravari; Masoud Pezeshki Rad
Journal:  Bull Emerg Trauma       Date:  2015-07

2.  Iatrogenic flow limiting arterial dissection.

Authors:  Brian Funaki
Journal:  Semin Intervent Radiol       Date:  2008-12       Impact factor: 1.513

3.  Vascular access complications: diagnosis and management.

Authors:  Raghu Kolluri; Brian Fowler; Shailesh Nandish
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-04

4.  An institutional approach to interventional strategies for complete vascular occlusions.

Authors:  Philip T Thrush; Chad A Mackman; Paul Lawrence; Aymen Naguib; Andrew R Yates; Stephen D Cassidy; Joanne L Chisolm; Sharon L Hill; John P Cheatham; Ralf J Holzer
Journal:  Pediatr Cardiol       Date:  2011-04-10       Impact factor: 1.655

5.  [Recent thrombosis of splanchnic veins : Two case reports of catheter-assisted local thrombolysis and thrombus aspiration].

Authors:  M Praktiknjo; C Meyer; C P Strassburg; J Trebicka
Journal:  Internist (Berl)       Date:  2017-01       Impact factor: 0.743

6.  The effects of ranitidine and hydrocortisone on the complications of femoral artery obstruction treated by streptokinase following cardiac catheterization in pediatric patients with congenital heart diseases.

Authors:  Noormohammad Noori; Ghasem Miri Aliabad; Mehdi Mohammadi; Maziar Mahjoubifard; Alireza Jahangiri Fard
Journal:  Iran Red Crescent Med J       Date:  2013-02-05       Impact factor: 0.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.